CancerPPD

This page gives details of Query peptides and provides facility to browse the same in CancerPPD database. Please wait while data is being retrieved. For more information see HELP page.

ID	PMID	SEQUENCE	NAME	LENGTH	ACTIVITY
1432	21955251	GIIKKIIIKKI	Cationic Amphiphilic	11	IC₅₀ = 160 µM
1433	21955251	GIIKKIIIKKIIIKKI	Cationic Amphiphilic	16	IC₅₀ = 15 µM
1434	21955251	GIIKKIIIKKIIIKKIIIKKI	Cationic Amphiphilic	21	IC₅₀ = 4 µM
1435	21955251	GIGKFLHSAKKFGKAFVGEIMNS	Magainin 2	23	IC₅₀ = >60 µM
1515	21252288	KWKSFAKTFKSAKKTVAHTALKAISS	L6A/L17A	26	IC₅₀=>83.6 µMo/L
1516	21252288	KWKSFLKTFKSAKKTVAHTAAKAISS	L17A/L21A	26	IC₅₀=>83.6 µMo/L
1517	21252288	KWKSFLKTFKSAKKTVAHTALKAISS	L17A	26	IC₅₀=>83.6 µMo/L
1518	21252288	KWKSFLKTFKSAKKTVAHTAAKAISS	L21A	26	IC₅₀=64.7 µMo/L
1519	21252288	KWKSFAKTFKSAKKTVLHTALKAISS	L6A	26	IC₅₀=58.6 µMo/L
1520	21252288	KWKSFLKTFKSAKKTVLHTALKAISS	P	26	IC₅₀=10.4 µMo/L
1521	21252288	KWKSFLKTFKSLKKTVLHTALKAISS	A12L	26	IC₅₀=3.8 µMo/L
1522	21252288	KWKSFLKTFKSAKKTVLHTLLKAISS	A20L	26	IC₅₀=4.3 µMo/L
1523	21252288	KWKSFLKTFKSLKKTVLHTLLKAISS	A12L/A20L	26	IC₅₀=2 µMo/L
1524	21252288	KWKSFLKTFKSLKKTVLHTLLKLISS	A12L/A20L/A23L	26	IC₅₀=2.2 µMo/L
1678	22641352	LLRHVVKILEKYL	Temporin-La	13	52.32 Inhibition ratio at 50 µg/ml
1679	22641352	LLRHVVKILSKYL	Temporin-Las	13	56.81 Inhibition ratio at 50 µg/ml
1680	22641352	RGDLLRHVVKILEKYL	RGD-La	16	73.09 Inhibition ratio at 50 µg/ml
1681	22641352	RGDLLRHVVKILSKYL	RGD-Las	16	78.045 Inhibition ratio at 50 µg/ml
2667	None	FALALKALKKALKKLKKALKKAL	Hecate AC	23	LD₅₀ =95 µg/ml
2668	None	FALALKALKKALKKLKKALKKAL	Hecate AM	23	LD₅₀ =50 µg/ml
2669	None	MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	SB-37 AC	38	LD₅₀ =150 µg/ml
2670	None	MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	SB-37 AM	38	LD₅₀ =>1000 µg/ml
2671	None	FAKKLAKKLKKLAKKLAKLALAL	SHIVA 10 AC	23	LD₅₀ =>1000 µg/ml
2672	None	FALAAKALKKLAKKLKKLAKKAL	FLAK01 AM	23	LD₅₀ =82 µg/ml
2673	None	FALALKALKKLLKKLKKLAKKAL	FLAK03 AM	23	LD₅₀ =145 µg/ml
2674	None	FALALKALKKLAKKLKKLAKKAL	FLAK04 AM	23	LD₅₀ =20 µg/ml
2675	None	FALAKLAKKAKAKLKKALKAL	FLAK05 AM	21	LD₅₀ =150 µg/ml
2676	None	FALALKALKKLKKALKKAL	FLAK06 AM	19	LD₅₀ =25 µg/ml
2677	None	FALALKALKKLKKALKKAL	FLAK06 AC	19	LD₅₀ =80 µg/ml
2678	None	FAKKLAKKLKKLAKLALAL	FLAK06 R-AC	19	LD₅₀ =260 µg/ml
2679	None	VALALKALKKALKKLKKALKKAL	KAL V	23	LD₅₀ =190 µg/ml
2680	None	FALALKKALKALKKAL	FLAK 17 AM	16	LD₅₀ =62 µg/ml
2681	None	FAKKLAKLAKKLAKLAL	FLAK 26 AM	17	LD₅₀ =27 µg/ml
2682	None	FAKKLAKLAKKLAKLALAL	FLAK 25 AM	19	Not Available
2683	None	FALALKALKKALkkLKKALKKAL	HECATE 2DAc	23	Not Available
2684	None	FAKKLAKLAKKLLAL	FLAK43 AM	15	LD₅₀ =35 µg/ml
2685	None	FAKKLAKLAKKALAL	FLAK44 AM	15	LD₅₀ =620 µg/ml
2686	None	FALAKKALKKAKKAL	FLAK62 AM	15	LD₅₀ =>1000 µg/ml
2687	None	FAKKLAKKLKKLAKLALAK	FLAK 06R-AM	19	LD₅₀ =185 µg/ml
2688	None	GIGKFLKKAKKFGKAFVKILKK	MSI-78 AM	22	Not Available
2689	None	FAKLLAKLAKKLL	FLAK50	13	LD₅₀ =15 µg/ml
2690	None	FAKKLAKLALKLAKL	FLAK51	15	LD₅₀ =22 µg/ml
2691	None	FAKKLAKKLAKLAL	FLAK57	14	LD₅₀ =160 µg/ml
2692	None	FAKKLKKLAKLAKKL	FLAK71	15	LD₅₀ =280 µg/ml
2693	None	FAKKALKALKKL	FLAK77	12	LD₅₀ =>1000 µg/ml
2694	None	VAKLLAKLAKKLL	FLAK50V	13	LD₅₀ =44 µg/ml
2695	None	FAKLLAKLAKKL	FLAK50F	12	Not Available
2696	None	VAKKLAKLAKKLAKLAL	FLAK26V AM	17	LD₅₀ =33 µg/ml
2697	None	KWKLFKKIGAVLKVL	CAME-15	15	LD₅₀ =30 µg/ml
2698	None	FAKLLAKLAKKAL	FLAK50C	13	LD₅₀ =190 µg/ml
2699	None	FAKLLAKALKKLL	FLAK50D	13	LD₅₀ =15 µg/ml
2700	None	FAKLLKLAAKKLL	FLAK 50E	13	LD₅₀ =300 µg/ml
2701	None	FAKLLAKKLL	FLAK80	10	LD₅₀ =830 µg/ml
2702	None	FAKKLAKALL	FLAK81	10	LD₅₀ =>1000 µg/ml
2703	None	FAKKLAKKLL	FLAK82	10	Not Available
2704	None	FAKLAKKLL	FLAK83M	9	LD₅₀ =>1000 µg/ml
2705	None	FAKKLAKLAKKLAKLAL	FLAK 26 Ac	17	LD₅₀ =170 µg/ml
2706	None	ILPWKWPWWPWRR	Indolicidin	13	LD₅₀ =345 µg/ml
2707	None	FAKALKALLKALKAL	FLAK 17 C	15	LD₅₀ =30 µg/ml
2708	None	FAKLLAKLAKAKL	FLAK 50H	13	LD₅₀ =210 µg/ml
2709	None	FAKLLAKLAKLKL	FLAK 50G	13	LD₅₀ =140 µg/ml
2710	None	FAKKLAKKLKKLAKKLAKKWKL	SHIVA DERIV P69 + KWKL	22	LD₅₀ =28 µg/ml
2711	None	FAKKLAKKLKKLAKKLAK	Shiva 10(1-18 AC)	18	LD₅₀ =570 µg/ml
2712	None	FAKKLAKKLKKLAKKLAKKWKL	SHIVA 10 PEPTIDE 71 + KWKL	22	LD₅₀ =240 µg/ml
2713	None	KWKLFKKKTKLFKKFAKKLAKKL	CA(1-7) Shiva10(1-16)	23	LD₅₀ =270 µg/ml
2714	None	FAKKLAKKLAKAL	FLAK 54	13	LD₅₀ =260 µg/ml
2715	None	FAKKLAKKLAKLL	FLAK 56	13	LD₅₀ =74 µg/ml
2716	None	FAKKLAKKLAKAAL	FLAK 58	14	LD₅₀ =380 µg/ml
2717	None	FAKKLAKKAKLAKKL	FLAK 72	15	LD₅₀ =>1000 µg/ml
2718	None	FAKKLKKLAKKL	FLAK 75	12	LD₅₀ =>1000 µg/ml
2719	None	KTKLFKKFAKKLAKKLKKLAKKL	SHIVA 10 (1-16) Ac	23	LD₅₀ =97 µg/ml
2720	None	KWKLFKKKTKLFKKFAKKLAKKL	CA(1-7) Shiva10(1-16)-COOH	23	LD₅₀ =19 µg/ml
2721	None	ILPWKWPWWPWRR	Indolocidin-ac	13	LD₅₀ =20 µg/ml
2722	None	FAKALAKLAKKLL	FLAK50B	13	LD₅₀ =670 µg/ml
2723	None	FAKLLAKLAKKAA	FLAK50J	13	LD₅₀ = >1000 µg/ml
2724	None	FAKLLALALKLKL	FLAK50I	13	LD₅₀ = >1000 µg/ml
2725	None	FAKLLAKLAKAKA	FLAK50K	13	LD₅₀ = >1000 µg/ml
2726	None	FAKLLAKLAKAKG	FLAK50L	13	LD₅₀ = >1000 µg/ml
2727	None	FAKKLAKKLKKLAKKLAKLALALKALALKAL	Shiva-11	31	LD₅₀ =175 µg/ml
2728	None	FAKKLAKKLKKLAKKLIGAVLKV	SHIVA 11[(1-16)ME(2-9]-COOH	23	LD₅₀ =180 µg/ml
2729	None	FAKLLAKALKLKL	FLAK 50N	13	LD₅₀ =170 µg/ml
2730	None	FAKLLAKALKKAL	FLAK 50O	13	LD₅₀ =43 µg/ml
2731	None	FAKLLAKALKKL	FLAK 50P	12	LD₅₀ =70 µg/ml
2732	None	KWKLFKKALKKLKKALKKAL	CA(1-& HECATE(11/23)	20	LD₅₀ =130 µg/ml
2733	None	KIAKVALAKLGIGAVLKVLTTGL	PYL-ME	23	LD₅₀ = >1000 µg/ml
2734	None	FAKKLAKLAKKL	FLAG26-D1	12	LD₅₀ =700 µg/ml
2735	None	MPKEKVFLKIEKMGRNIRN	VISHNU3	19	LD₅₀ = >1000 µg/ml
2736	None	GIGAVLKVLTTGLPALISWIKRKRQQ	MELITTIIN	26	LD₅₀ =35 µg/ml
2737	None	FAKKLAKLAKKLAKAL	FLAK26-D2	16	LD₅₀ =>1000 µg/ml
2738	None	FAKKLLAKALKL	FLAG26-D3	12	LD₅₀ =540 µg/ml
2739	None	FAKFLAKFLKKAL	FLAK50 Q1	13	LD₅₀ =7 µg/ml
2740	None	FAKLLFKALKKAL	FLAK50 Q2	13	LD₅₀ =660 µg/ml
2741	None	FAKLLAKFLKKAL	FLAK50 Q3	13	LD₅₀ =190 µg/ml
2742	None	FAKLLAKAFKKAL	FLAK50 Q4	13	LD₅₀ = >1000 µg/ml
2743	None	FAKLFAKAFKKAL	FLAK50 Q5	13	LD₅₀ = >1000 µg/ml
2744	None	FAKLLAKALKKFL	FLAK50 Q6	13	LD₅₀ =87 µg/ml
2745	None	FAKLLAKALKKFAL	FLAK50 Q7	14	LD₅₀ =30 µg/ml
2746	None	FAKLLAKLAKKFAL	FLAK50 Q8	14	LD₅₀ =810 µg/ml
2747	None	FAKLFAKLAKKFAL	FLAK50 Q9	14	LD₅₀ =830 µg/ml
2748	None	FKLAFKLAKKAFL	FLAK50 Q10	13	LD₅₀ =780 µg/ml
2749	None	FAKLLAKLAK	FLAK50 T1	10	LD₅₀ =940 µg/ml
2750	None	FAKLLAKLAKKVL	FLAK50 T2	13	LD₅₀ =14 µg/ml
2751	None	FAKLLAKLAKKIL	FLAK50 T3	13	LD₅₀ =220 µg/ml
2752	None	FAKLLAKLAKKEL	FLAK50 T4	13	LD₅₀ = >1000 µg/ml
2753	None	FAKLLAKLAKKSL	FLAK50 T5	13	LD₅₀ =610 µg/ml
2754	None	FAKLA	FLAK90	5	LD₅₀ =700 µg/ml
2755	None	FAKLF	FLAK91	5	LD₅₀ =550 µg/ml
2756	None	KAKLF	FLAK92	5	LD₅₀ = >1000 µg/ml
2757	None	KWKLF	FLAK93	5	LD₅₀ = >1000 µg/ml
2758	None	FGKGIGKVGKKLL	FLAK50 Z1	13	LD₅₀ = >1000 µg/ml
2759	None	FAFGKGIGKVGKKLL	FLAK50 Z2	15	LD₅₀ = >1000 µg/ml
2760	None	FAKAIAKIAFGKGIGKVGKKLL	FLAK50 Z3	22	LD₅₀ = >1000 µg/ml
2761	None	FAKLWAKLAFGKGIGKVGKKLL	FLAK50 Z4	22	LD₅₀ =215 µg/ml
2762	None	FAKLWAKLAKKL	FLAK50 Z5	12	LD₅₀ =400 µg/ml
2763	None	FAKGVGKVGKKAL	FLAK50 Z6	13	LD₅₀ = >1000 µg/ml
2764	None	FAFGKGIGKIGKKGL	FLAK50 Z7	15	LD₅₀ = >1000 µg/ml
2765	None	FAKIIAKIAKIAKKIL	FLAK50 Z8	16	LD₅₀ = >1000 µg/ml
2766	None	FAFAKIIAKIAKKII	FLAK50 Z9	15	LD₅₀ =285 µg/ml
2767	None	FALALKA	FLAK94	7	LD₅₀ = >1000 µg/ml
2768	None	KWKLAKKALALL	FLAK93B	12	LD₅₀ =55 µg/ml
2769	None	FAKIIAKIAKKI	FLAK50 Z10	12	LD₅₀ =>1000 µg/ml
2770	None	FALALKALKKAL	FLAK96	12	LD₅₀ =275 µg/ml
2771	None	FALKALKK	FLAK97	8	LD₅₀ =240 µg/ml
2772	None	KYKKALKKLAKLL	FLAK98	13	LD₅₀ =640 µg/ml
2773	None	FKRLAKIKVLRLAKIKR	FKRLA	17	LD₅₀ = >1000 µg/ml
2774	None	FAKLAKKALAKLL	FLAK91B	13	LD₅₀ = >1000 µg/ml
2775	None	KAKLAKKALAKLL	FLAK92B	13	LD₅₀ = >1000 µg/ml
2776	None	KLALKLALKALKAAKLA	FLAK99	17	LD₅₀ =320 µg/ml
2777	None	FAKLLAKLAKK	FLAK50T6	11	LD₅₀ =>1000 µg/ml
2778	None	FAKLLAKLAKKGL	FLAK50T7	13	LD₅₀ =>1000 µg/ml
2779	None	FALKALKKLKKALKKAL	FLAK95	17	LD₅₀ =140 µg/ml
2780	None	VAKLLAKLAKKVL	FLAK50T8	13	LD₅₀ = >1000 µg/ml
2781	None	YAKLLAKLAKKAL	FLAK50T9	13	LD₅₀ = >1000 µg/ml
2782	None	KLLKLLLKLYKKLLKLL	FLAK100-CO2H	17	LD₅₀ = >1000 µg/ml
2783	None	FAVGLRAIKRALKKLRRGVRKVAKDL	FAGVL	26	LD₅₀ = >1000 µg/ml
2784	None	KLAKKLAKLAKLAKAL	Modelin-5	16	LD₅₀ =275 µg/ml
2785	None	KLAKKLAKLAKLAKAL	Modelin-5-CO2H	16	LD₅₀ =550 µg/ml
2786	None	FALALKALKKL	FLAK120	9	LD₅₀ =400 µg/ml
2787	None	FALAKALKKAL	FLAK121	11	LD₅₀ =>1000 µg/ml
2788	None	FALALKLAKKAL	FLAK96B	12	LD₅₀ =325 µg/ml
2789	None	FALLKL	FLAK96G	6	LD₅₀ = >1000 µg/ml
2790	None	FALALKALKK	FLAK96F	10	LD₅₀ = >1000 µg/ml
2791	None	FALKALKKAL	FLAK96C	10	LD₅₀ = >1000 µg/ml
2792	None	FALLKALKKAL	FLAK96D	11	LD₅₀ =820 µg/ml
2793	None	KFKKLAKKF	Modelin-8D	9	LD₅₀ = >1000 µg/ml
2794	None	KFKKLAKKW	Modelin-8E	9	LD₅₀ =510 µg/ml
2795	None	FALALKALKKA	Flak 96H	11	LD₅₀ = >1000 µg/ml
2796	None	FALLKALLKKAL	Flak 96I	12	LD₅₀ =380 µg/ml
2797	None	FALALKLAKKL	Flak 96J	11	LD₅₀ = >1000 µg/ml
2798	None	LKKLAKLALAF	Flak 96L	11	LD₅₀ = >1000 µg/ml
2799	None	VALALKALKKL	FLAK-120G	11	LD₅₀ =760 µg/ml
2800	None	FALALKLKKL	FLAK-120D	10	LD₅₀ = >1000 µg/ml
2801	None	FALALKAKKL	FLAK-120C	10	LD₅₀ = >1000 µg/ml
2802	None	FALA	FLAK-120B	4	LD₅₀ = >1000 µg/ml
2803	None	WALAL	FLAK-120F	5	LD₅₀ =302 µg/ml
2804	None	GIGKFLHAAKKFAKAFVAEIMNS	Magainin2wisc	23	LD₅₀ =125 µg/ml
2805	None	FAKKFAKKFKKFAKKFAKFAFAF	D2A21	23	LD₅₀ =170 µg/ml
2806	None	KKVVFKVKFK	KSL-1	10	LD₅₀ = >1000 µg/ml
2807	None	FKVKFKVKVK	KSL-7	10	LD₅₀ =>1000 µg/ml
2808	None	LPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG	LSB-37	38	LD₅₀ =250 µg/ml
2809	None	FAKKLAKKLKKLAKKLAKLAKKL	Anubis-2	23	LD₅₀ =100 µg/ml
2839	24246647	GIIKKIIKKI	Short α-helical peptides	10	99% Cytotoxicity at 4 µM Approx
2840	24246647	GIIKKIIKKIIKKI	Short α-helical peptides	14	95% Cytotoxicity at 4 µM Approx
2841	24246647	GIIKKIIKKIIKKIIKKI	Short α-helical peptides	18	80% Cytotoxicity at 4 µM Approx
2925	23598079	GFIFHIIKGLFHAGKMIHGLV	Epinecidin-1	21	45% Cytotoxicity at 50 mg/L
2926	23598079	GFIFHIIKGLFHAGKMIHGLV	Epinecidin-1	21	38% Cytotoxicity at 25 mg/L
2927	23598079	GFIFHIIKGLFHAGKMIHGLV	Epinecidin-1	21	75% Cytotoxicity at 50 mg/L
2928	23598079	GFIFHIIKGLFHAGKMIHGLV	Epinecidin-1	21	65% Cytotoxicity at 25 mg/L
2929	23598079	GFIFHIIKGLFHAGKMIHGLV	Epinecidin-1	21	75 % Cytotoxicity at 50 mg/L
2930	23598079	GFIFHIIKGLFHAGKMIHGLV	Epinecidin-1	21	65% Cytotoxicity at 25 mg/L
2931	23598079	GFIFHIIKGLFHAGKMIHGLV	Epinecidin-1	21	83% Cytotoxicity at 50 mg/L
2932	23598079	GFIFHIIKGLFHAGKMIHGLV	Epinecidin-1	21	77 % Cytotoxicity at 25 mg/L
2956	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	60 % Cytotoxicity at 50 mg/L
2957	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	50 % Cytotoxicity at 25 mg/L
2958	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	8 % Cytotoxicity at 12.5 mg/L
2959	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	10 % Cytotoxicity at 6.25 mg/L
2960	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	5 % Cytotoxicity at 3.125 mg/L
2961	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	75 % Cytotoxicity at 50 mg/L
2962	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	70 % Cytotoxicity at 25 mg/L
2963	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	5 % Cytotoxicity at 12.5 mg/L
2964	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	7 % Cytotoxicity at 6.25 mg/L
2965	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	10 % Cytotoxicity at 3.125 mg/L
2966	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	76 % Cytotoxicity at 50 mg/L
2967	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	70 % Cytotoxicity at 25 mg/L
2968	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	12 % Cytotoxicity at 12.5 mg/L
2969	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	4 % Cytotoxicity at 6.25 mg/L
2970	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	4 % Cytotoxicity at 3.125 mg/L
2971	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	90 % Cytotoxicity at 50 mg/L
2972	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	75 % Cytotoxicity at 25 mg/L
2973	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	8 % Cytotoxicity at 12.5 mg/L
2974	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	3 % Cytotoxicity at 6.25 mg/L
2975	23598079	FIFHIIKGLFHAGKMI	Epinecidin-8	16	3 % Cytotoxicity at 3.125 mg/L
2996	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	62 % Cytotoxicity at 50 mg/L
2997	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	44 % Cytotoxicity at 25 mg/L
2998	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	4 % Cytotoxicity at 12.5 mg/L
2999	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	75 % Cytotoxicity at 50 mg/L
3000	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	70 % Cytotoxicity at 25 mg/L
3001	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	4 % Cytotoxicity at 3.125 mg/L
3002	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	78 % Cytotoxicity at 50 mg/L
3003	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	68 % Cytotoxicity at 25 mg/L
3004	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	4 % Cytotoxicity at 12.5 mg/L
3005	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	5 % Cytotoxicity at 6.25 mg/L
3006	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	10 % Cytotoxicity at 3.125 mg/L
3007	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	90 % Cytotoxicity at 50 mg/L
3008	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	80 % Cytotoxicity at 25 mg/L
3009	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	15 % Cytotoxicity at 12.5 mg/L
3010	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	12 % Cytotoxicity at 6.25 mg/L
3011	23598079	GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE	Pardaxin-1	33	5 % Cytotoxicity at 3.125 mg/L
3032	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	70 % Cytotoxicity at 50 mg/L
3033	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	60 % Cytotoxicity at 25 mg/L
3034	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	4 % Cytotoxicity at 12.5 mg/L
3035	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	5 % Cytotoxicity at 6.25 mg/L
3036	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	1 % Cytotoxicity at 3.125 mg/L
3037	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	78 % Cytotoxicity at 50 mg/L
3038	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	70 % Cytotoxicity at 25 mg/L
3039	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	10 % Cytotoxicity at 12.5 mg/L
3040	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	10 % Cytotoxicity at 6.25 mg/L
3041	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	5 % Cytotoxicity at 3.125 mg/L
3042	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	82 % Cytotoxicity at 50 mg/L
3043	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	70 % Cytotoxicity at 25 mg/L
3044	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	18 % Cytotoxicity at 12.5 mg/L
3045	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	4 % Cytotoxicity at 6.25 mg/L
3046	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	10 % Cytotoxicity at 3.125 mg/L
3047	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	90 % Cytotoxicity at 50 mg/L
3048	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	82 % Cytotoxicity at 25 mg/L
3049	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	18 % Cytotoxicity at 12.5 mg/L
3050	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	18 % Cytotoxicity at 6.25 mg/L
3051	23598079	GFFALIPKIISSPLFKTLLSAVGSALS	Pardaxin-6	27	18 % Cytotoxicity at 3.125 mg/L
3140	23627474	CHHNLTHAC	PTPRJ-pep19	9	4.5 ± 0.1.4% cell growth inhibition at 160 µM in 48 hours
3141	23627474	CHHNLTHAC	PTPRJ-pep19	9	19 ± 2.82% cell growth inhibition at 160 µM in 72 hours
3142	23627474	CHHNLTHAC	PTPRJ-pep19.0	9	4 ± 1.4% cell growth inhibition at 160 µM in 72 hours
3143	23627474	CAHNLTHAC	PTPRJ-pep19.2	9	16.5 ± 2.12% cell growth inhibition at 160 µM in 24 hours
3144	23627474	CAHNLTHAC	PTPRJ-pep19.2	9	30 ± 2.82% cell growth inhibition at 160 µM in 48 hours
3145	23627474	CAHNLTHAC	PTPRJ-pep19.2	9	32.0 ± 4.2% cell growth inhibition at 160 µM in 72 hours
3146	23627474	CHANLTHAC	PTPRJ-pep19.3	9	28 ± 5.5% cell growth inhibition at 160 µM in 24 hours
3147	23627474	CHANLTHAC	PTPRJ-pep19.3	9	46 ± 4.2% cell growth inhibition at 160 µM in 48 hours
3148	23627474	CHANLTHAC	PTPRJ-pep19.3	9	51 ± 1.4% cell growth inhibition at 160 µM in 72 hours
3149	23627474	CHHALTHAC	PTPRJ-pep19.4	9	48.0 ± 2.82% cell growth inhibition at 160 µM in 24 hours
3150	23627474	CHHALTHAC	PTPRJ-pep19.4	9	62.5 ± 4.9% cell growth inhibition at 160 µM in 48 hours
3151	23627474	CHHALTHAC	PTPRJ-pep19.4	9	66.5 ± 2.12% cell growth inhibition at 160 µM in 72 hours
3152	23627474	CHHNATHAC	PTPRJ-pep19.5	9	2 ± 1.5% cell growth inhibition at 160 µM in 48 hours
3153	23627474	CHHNATHAC	PTPRJ-pep19.5	9	19 ± 4.2% cell growth inhibition at 160 µM in 72 hours
3154	23627474	CHHNLAHAC	PTPRJ-pep19.6	9	19 ± 4.2% cell growth inhibition at 160 µM in 72 hours
3155	23627474	CHHNLTAAC	PTPRJ-pep19.7	9	4.5 ± 2.13% cell growth inhibition at 160 µM in 48 hours
3156	23627474	CHHNLTAAC	PTPRJ-pep19.7	9	20 ± 1.4% cell growth inhibition at 160 µM in 72 hours
3189	17787026	(K-Aib-C(CH2CO-2'-Pac))2	Dimer of peptide-paclitaxel conjugate	3	IC₅₀ =1.31nM
3192	17787026	(K-Aib-C(CH2CO-2'-Pac))3	Trimer of peptide-paclitaxel conjugate	3	IC₅₀ =1.70nM
3195	17787026	(K-Aib-C(CH2CO-2'-Pac))4	Tetramer of peptide-paclitaxel conjugate	3	IC₅₀ =0.96nM
3495	22100226	VNWKKILGKIIKVVK	LL-III	15	IC₅₀ = 4±1 µM
3496	22100226	VNWKKILAKIIKVVK	LL-III/1	15	IC₅₀ = 3±1 µM
3497	22100226	NVWKKILGKIIKVVK	LL-III/2	15	Not tested
3498	22100226	VNWKKILKKIIKVVK	LL-III/3	15	Not tested
3499	22100226	VNWKKILGKIKKVVK	LL-III/4	15	IC₅₀ = 7±1 µM
3500	22100226	VNWKKILPKIIKVVK	LL-III/6	15	IC₅₀ > 40 µM
3501	22100226	VNWKKILGKIIKVVK	LL-III/8	15	IC₅₀ = 12±1 µM
3502	22100226	VNWKKILGKIIKVVK	LL-III/9	15	IC₅₀ = 3±1 µM
3503	22100226	KNWKKILGKIIKVVK	LL-III/10	15	IC₅₀ = 9±4 µM
3504	22100226	VNWKKIILGKIIKVVK	LL-III/11	15	IC₅₀ = 8±1 µM
3505	22100226	vnwkkilgkiikvvk	LL-III/12	15	IC₅₀ = 6±2 µM
3506	22100226	VNFKKLLGKLLKVVK	LL-III/15	15	IC₅₀ = 7±1 µM
3507	22100226	VN-Nal-KKLLGKLLKVVK	LL-III/16	15	IC₅₀ = 6±1 µM
3508	22100226	VNWRRILGRIIRVVR	LL-III/17	15	IC₅₀= 9 µM
3509	22100226	KNWKKILKKIIKVVK	LL-III/18	15	IC₅₀ = 3 µM
3510	22100226	VNWKK-Aib-LGK-Aib-IK-Aib-VK	LL-III/19	15	IC₅₀ = 3±1 µM
3511	22100226	KNWKK-Aib-LKK-Aib-IK-Aib-VK	LL-III/22	15	IC₅₀ = 11±7 µM
3512	22100226	VNWKKLLGKLLKVVK	LL-III/23	15	IC₅₀ = 4 µM
3513	22100226	VNWOOILGOIIOVVO	LL-III/24	15	IC₅₀ = 3±1 µM
3514	22100226	vnwkkllgkllkvvk	LL-III/25	15	IC₅₀ = 4±2 µM
3515	22100226	VYWKKILGKIIKVVK	LL-III/26	15	IC₅₀ = 5±1 µM
3516	22100226	VNWKKVLGKVVKVVK	LL-III/27	15	IC₅₀ = 13±2 µM
3517	22100226	NKWKKILGKIIKVVK	LL-III/34	15	IC₅₀ = 5±2 µM
3518	22100226	VNWKKILAKIIKVVK	LL-III/36	15	IC₅₀ = 8 µM
3586	22100226	GFGMALKLLKKVL	MAC1	13	IC₅₀ = 10±4 µM
3587	22100226	GTGLPMSERRKIMLMMR	MAC2	17	IC₅₀ > 100 µM
3588	22100226	gfgmalkllkkvl	MAC1/1	13	IC₅₀ = 12±4 µM
3589	22100226	AFGMALKLLKKVL	MAC1/2	13	IC₅₀ = 16±3 µM
3590	22100226	LFGMALKLLKKVL	MAC1/3	13	IC₅₀ = 9±2 µM
3591	22100226	GFGMALKLLKKVL	MAC1/4	13	IC₅₀ = 15±5 µM
3592	22100226	GFGMALKLLKKVL	MAC1/6	13	IC₅₀ = 8±2 µM
3593	22100226	GFKMALKLLKKVL	MAC1/9	13	IC₅₀ = 8±1 µM
3594	22100226	GFKMALKLLKKVL	MAC1/10	13	IC₅₀ = 15±6 µM
3595	22100226	GFGMALKLLKKVL	MAC1/16	13	IC₅₀ = 32±2 µM
3596	22100226	GFGMALKLLKKVL	MAC1/19	13	IC₅₀ = 21±4 µM
3597	22100226	GFGMALOLLOOVL	MAC1/20	13	IC₅₀ = 10±1 µM
3598	22100226	GFGMALRLLRRVL	MAC1/21	13	IC₅₀ = 9±3 µM
3599	22100226	GFGMALKL-(AC6C)-KKVL	MAC1/24	13	IC₅₀ = 8±2 µM
3600	22100226	GFGMALK-(AC6C)-LKKVL	MAC1/25	13	IC₅₀ = 7±1 µM
3601	22100226	GFGMA-(AC6C)-KLLKKVL	MAC1/26	13	IC₅₀ = 8±2 µM
3634	22100226	GMWSKILGHLIR	HAL-1	12	IC₅₀ = 11±2 µM
3635	22100226	gmwskilghlir	HAL-1/22	12	IC₅₀ = 15±3 µM
3636	22100226	GMWSKILGHLIK	HAL-1/6	12	IC₅₀ = 15±1 µM
3637	22100226	GMWSKILGHLKR	HAL-1/4	12	IC₅₀ > 100 µM
3638	22100226	GMWSKILGKLIR	HAL-1/9	12	IC₅₀ = 9±1 µM
3639	22100226	GMWSKILKHLIR	HAL-1/18	12	IC₅₀ = 4±2 µM
3640	22100226	GMWKKILGHLIR	HAL-1/5	12	IC₅₀ = 9±1 µM
3641	22100226	GKWSKILGHLIR	HAL-1/12	12	IC₅₀ = 43±14 µM
3642	22100226	KMWSKILGHLIR	HAL-1/17	12	IC₅₀ = 35±3 µM
3643	22100226	GMWKKILGKLIR	HAL-1/10	12	IC₅₀ = 13±2 µM
3644	22100226	GKWSKILGKLIR	HAL-1/20	12	IC₅₀ = 22±3 µM
3645	22100226	GKWKKILGHLIR	HAL-1/19	12	IC₅₀ > 100 µM
3646	22100226	GKWKKILGKLIR	HAL-1/21	12	IC₅₀ = 30±3 µM
3647	22100226	GMWSKILGHLIR	HAL-1/29	12	IC₅₀ > 100 µM
3648	22100226	GMWSKLLGHLLR	HAL-1/15	12	IC₅₀ = 14±2 µM
3649	22100226	GKWMSLLKHILK	HAL-2	12	IC₅₀ = 12±1 µM
3650	22100226	gkwmsllkhilk	HAL-2/22	12	IC₅₀ = 12 µM
3651	22100226	GKWMSLLKKILK	HAL-2/4	12	IC₅₀ > 40 µM
3652	22100226	GKWMKLLKHILK	HAL-2/2	12	IC₅₀ = 6±1 µM
3653	22100226	GKWKSLLKHILK	HAL-2/1	12	IC₅₀ = 14±2 µM
3654	22100226	GKWMSLLKHILK	HAL-2/8	12	IC₅₀ = 15±3 µM
3655	22100226	GKWMSLLKHIWK	HAL-2/18	12	IC₅₀ = 14±2 µM
3656	22100226	GKWMSLLKHWLK	HAL-2/19	12	IC₅₀ = 16±4 µM
3657	22100226	GKWMSLWKHILK	HAL-2/20	12	IC₅₀ = 30±5 µM
3658	22100226	GKFMSLLKHILK	HAL-2/24	12	IC₅₀ = 34 µM
3659	22100226	GKWMSFLKHILK	HAL-2/6	12	IC₅₀ = 23±3 µM
3660	22100226	GKWMTLLKHILK	HAL-2/13	12	IC₅₀ = 13±3 µM
3661	22100226	GKWLSLLKHILK	HAL-2/11	12	IC₅₀ = 14±3 µM
3755	22837667	KWKSFLKTFKSLKKTVLHTLLKAISS	Peptide P	26	IC₅₀= 1.71±0.07 µMol/L
3756	22837667	KWKSFLkTFKSLKKTVLHTLLKAISS	Peptide K7D	26	IC₅₀= 1.29±0.03 µMol/L
3757	22837667	KWKSFLKTFKSLKkTVLHTLLKAISS	Peptide K14D	26	IC₅₀= 1.52±0.05 µMol/L
3758	22837667	KWKSFLKTFKSLKKTVLHTLLkAISS	Peptide K22D	26	IC₅₀= 1.39±0.02 µMol/L
3759	22837667	KWKSFLkTFKSLKkTVLHTLLKAISS	Peptide K7D /K14D	26	IC₅₀= 2.06±0.01 µMol/L
3760	22837667	KWKSFLKTFKSLKkTVLHTLLkAISS	Peptide K14D/K22D	26	IC₅₀= 1.40±0.09 µMol/L
3761	22837667	KWKSFLkTFKSLKkTVLHTLLKAISS	Peptide K7D /K14D/K22D	26	IC₅₀= 4.45±0.19 µMol/L
3762	22837667	KWKSFLkTFkSLKkTVLHTLLkAISS	Peptide K7D /K10D/K14D/K22D	26	IC₅₀= 4.79±0.23 µMol/L
3763	22837667	KWkSFLkTFkSLKkTVLHTLLkAISS	Peptide K3D/K7D /K10D/K14D/K22D	26	IC₅₀= 20.41±0.64 µMol/L
3764	22837667	kWkSFLkTFkSLKkTVLHTLLkAISS	Peptide K1D/K3D/K7D /K10D/K14D/K22D	26	IC₅₀= 18.07±0.48 µMol/L
3765	22837667	KWKSFlKTFKSLKKTVLHTLLKAISS	Peptide L6D	26	IC₅₀= 2.23±0.10 µMol/L
3766	22837667	KWKSFLKTFKSlKKTVLHTLLKAISS	Peptide L12D	26	IC₅₀= 2.63±0.07 µMol/L
3767	22837667	KWKSFLKTFKSLKKTVLHTlLKAISS	Peptide L20D	26	IC₅₀= 2.33±0.06 µMol/L
3768	22837667	KWKSFlKTFKSlKKTVLHTLLKAISS	Peptide L6D/L12D	26	IC₅₀= 3.01±0.08 µMol/L
3769	22837667	KWKSFLKTFKSlKKTVLHTlLKAISS	Peptide L12D/L20D	26	IC₅₀= 3.14±0.06 µMol/L
3770	22837667	KWKSFlKTFKSlKKTVLHTlLKAISS	Peptide L6D/L12D/L20D	26	IC₅₀= 7.80±0.26 µMol/L
3771	22837667	KWKSFlKTFKSlKKTVlHTlLKAISS	Peptide L6D/L12D/L17D/L20D	26	IC₅₀= 9.69±0.38 µMol/L
3772	22837667	KWKSFlKTFKSlKKTVlHTllKAISS	Peptide L6D/L12D/L17D/L20D/L21D	26	IC₅₀= 12.88±0.15 µMol/L
3827	23034893	MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYP SDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYW ECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN	AAD (or Aa-Pri1)	145	At 2.5 µM concentration,decrease in cell vibility= 70%
3851	16722632	YA*	8	2	10% inhibition at 10^-5
3852	16722632	YA*	8	2	8.2% inhibition at 10^-4
3853	16722632	YA*	8	2	36.1% inhibition at 10^-3
3876	16722632	YSA*	9	3	7.5% inhibition at 10^-6
3877	16722632	YSA*	9	3	6.1% inhibition at 10^-5
3878	16722632	YSA*	9	3	3.1% inhibition at 10^-4
3879	16722632	YSA*	9	3	14.8% inhibition at 10^-3
3901	16722632	YSA*	10	3	7.2% inhibition at 10^-6
3902	16722632	YSA*	10	3	17.1% inhibition at 10^-5
3903	16722632	YSA*	10	3	11.0% inhibition at 10^-4
3904	16722632	YSA*	10	3	20.5% inhibition at 10^-3
3921	16722632	YSA*G	15	4	9.8% inhibition at 10^-6M
3922	16722632	YSA*G	15	4	7.3% inhibition at 10^-5M
3923	16722632	YSA*G	15	4	9.9% inhibition at 10^-4M
3924	16722632	YSA*G	15	4	28.2% inhibition at 10^-3M
3946	16722632	YRA*G	16	4	11.0% inhibition at 10^-6M
3947	16722632	YRA*G	16	4	11.7% inhibition at 10^-5M
3948	16722632	YRA*G	16	4	11.6% inhibition at 10^-4M
3949	16722632	YRA*G	16	4	28.2% inhibition at 10^-3M
3970	16722632	YA*GFM	17	5	4.9% inhibition at 10^-6M
3971	16722632	YA*GFM	17	5	10.2% inhibition at 10^-5M
3972	16722632	YA*GFM	17	5	13.3% inhibition at 10^-4M
3973	16722632	YA*GFM	17	5	28.0% inhibition at 10^-3M
3995	16722632	YA*GFM	18	5	8.5% inhibition at 10^-6M
3996	16722632	YA*GFM	18	5	9.5% inhibition at 10^-5M
3997	16722632	YA*GFM	18	5	15.4% inhibition at 10^-4M
3998	16722632	YA*GFM	18	5	24.1% inhibition at 10^-3M
4019	16722632	YGGFMA*	23	6	9.3% inhibition at 10^-3M
4191	15467750	GRKKRRQRRR	HIV-TAT48-57	10	7% apoptosis at 10 µM
4192	15467750	GRKKRRQRRR	HIV-TAT48-57	10	15% apoptosis at 20 µM
4193	15467750	GRKKRRQRRR	HIV-TAT48-57	10	35% apoptosis at 30 µM
4194	15467750	GRKKRRQRRR	HIV-TAT48-57	10	65% apoptosis at 50 µM
4195	15467750	GRKKRRQRRRGGWMWVTNLRTD	TAT-Ras-GAP317-326	22	15% apoptosis at 10 µM
4196	15467750	GRKKRRQRRRGGWMWVTNLRTD	TAT-Ras-GAP317-326	22	47% apoptosis at 20 µM
4197	15467750	GRKKRRQRRRGGWMWVTNLRTD	TAT-Ras-GAP317-326	22	72% apoptosis at 30 µM
4198	15467750	GRKKRRQRRRGGWMWVTNLRTD	TAT-Ras-GAP317-326	22	79% apoptosis at 50 µM
4602	12417587	GIGKFLHSAKKWGKAFVGQIMNC	MG2d	23	at 1 µM 90-100% viablity
4603	12417587	TRSSRAGLQWPVGRVHRLLRKGGC	BF2d	24	at 1 µM 90-100% viablity
4604	12417587	YGRKKRRQRRR	Tat (47-57)	11	at 1 µM 90-100% viablity
4605	12417587	TRSSRAGLQWPVGRVHRLLRKGGC	BF2d	24	at 10 µM 90-95% viablity
4606	12417587	YGRKKRRQRRR	Tat (47-57)	11	at 10 µM 80% viablity
4607	12417587	TRSSRAGLQWPVGRVHRLLRKGGC	BF2d	24	at 100 µM 90-100% viablity
4608	12417587	YGRKKRRQRRR	Tat (47-57)	11	at 100 µM 60% viablity
4613	20802991	CSSRTMHHC	Peptide-20	9	at 100 µM 50% viablity

CancerPPD :Database of Anticancer peptides and Proteins

Browse Result page of CancerPPD